Literature DB >> 23430822

Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease.

A Dursun1, R K Ozgül, S Sivri, A Tokatlı, A Güzel, L Mesci, M Kılıç, D Aliefendioglu, F Ozçay, M Gündüz, T Coşkun.   

Abstract

Tyrosinemia type I (OMIM 276700) is a rare, autosomal recessive disorder caused by a deficiency in the fumarylacetoacetate hydrolase (FAH) enzyme. This study examined the spectrum of FAH gene mutation in 32 patients with tyrosinemia type I. In addition, clinical and biochemical findings were evaluated to establish a genotype-phenotype relationship in the patients. Mutation screening was performed using a 50K custom-designed resequencing microarray chip (TR_06_01r520489, Affymetrix) and sequencing analysis. Of the 12 different mutations found, 6 are categorized as novel. Three of the mutations-IVS6-1G>A, D233V, and IVS3-3C>G-are the most common in Turkish patients, comprising 25%, 17.1%, and 12.5% of mutant alleles, respectively.Clinical evaluations suggest that the spectrum of symptoms observed in the patients with very early and early disease were of the more nonspecific form, whereas the patients with late-presenting disease had more of the distinctive form over the course of the disease. This study adds support to the notion that the D233V mutation is specific to the Turkish population.

Entities:  

Year:  2011        PMID: 23430822      PMCID: PMC3509809          DOI: 10.1007/8904_2011_10

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  13 in total

1.  Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I.

Authors:  Orly N Elpeleg; Avraham Shaag; Elizabeth Holme; Ghaleb Zughayar; Suzi Ronen; Drora Fisher; Haggit Hurvitz
Journal:  Hum Mutat       Date:  2002-01       Impact factor: 4.878

2.  Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age.

Authors:  M E Blohm; D Vesterling-Hörner; G Calaminus; U Göbel
Journal:  Pediatr Hematol Oncol       Date:  1998 Mar-Apr       Impact factor: 1.969

Review 3.  Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.

Authors:  M St-Louis; R M Tanguay
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

4.  Crystal structure and mechanism of a carbon-carbon bond hydrolase.

Authors:  D E Timm; H A Mueller; P Bhanumoorthy; J M Harp; G J Bunick
Journal:  Structure       Date:  1999-09-15       Impact factor: 5.006

5.  Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.

Authors:  F J van Spronsen; Y Thomasse; G P Smit; J V Leonard; P T Clayton; V Fidler; R Berger; H S Heymans
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

6.  Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.

Authors:  J A Arranz; F Piñol; L Kozak; C Pérez-Cerdá; B Cormand; M Ugarte; E Riudor
Journal:  Hum Mutat       Date:  2002-09       Impact factor: 4.878

7.  Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I.

Authors:  H Awata; F Endo; A Tanoue; A Kitano; Y Nakano; I Matsuda
Journal:  Biochim Biophys Acta       Date:  1994-05-25

8.  Fumarylacetoacetase mutations in tyrosinaemia type I.

Authors:  H Rootwelt; K Høie; R Berger; E A Kvittingen
Journal:  Hum Mutat       Date:  1996       Impact factor: 4.878

9.  Serum alpha fetoprotein (AFP) levels in normal infants.

Authors:  J T Wu; L Book; K Sudar
Journal:  Pediatr Res       Date:  1981-01       Impact factor: 3.756

10.  Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.

Authors:  A J Bergman; I E van den Berg; W Brink; B T Poll-The; J K Ploos van Amstel; R Berger
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

View more
  5 in total

1.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

2.  Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.

Authors:  Iratxe Macias; Ana Laín; Ganeko Bernardo-Seisdedos; David Gil; Esperanza Gonzalez; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2019-07-12       Impact factor: 5.157

3.  Type 1 tyrosinemia in Finland: a nationwide study.

Authors:  Linnea Äärelä; Pauliina Hiltunen; Tea Soini; Nina Vuorela; Heini Huhtala; Pasi I Nevalainen; Markku Heikinheimo; Laura Kivelä; Kalle Kurppa
Journal:  Orphanet J Rare Dis       Date:  2020-10-12       Impact factor: 4.123

4.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

Review 5.  Protein Degradation and the Pathologic Basis of Phenylketonuria and Hereditary Tyrosinemia.

Authors:  Neha Sarodaya; Bharathi Suresh; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.